A Phase 1 study of KBP-5209 in patients with advanced solid tumors

B
Bert O'Neil, MD

Primary Investigator

J
Jessica MacLean

Primary Investigator

Overview

The purpose of this study is to find the highest dose of study drug (KBP-5209) that can be given safely in humans, and to determine the immediate and long-term side effects of treatment with KBP-5209 when it is taken orally every day on a continuous basis.

Description

The purpose of this study is to establish a safe dose range based on side effects and to get an idea of how well the drug might work in treating cancer.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    solid tumor
  • Age: Between 18 Years - 100 Years
  • Gender: All
Updated on 20 Nov 2022. Study ID: 1501374278 (5209-CPK-1001

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center